RNA m^(6)A修饰在肿瘤发展及免疫治疗中的研究进展

Research Progress on RNA m^(6)A Modification in Tumor Development and Immunotherapy

N6-甲基腺嘌呤(N6-methyladenosine,m^(6)A)是指在腺苷的N6位置发生的甲基化修饰,是真核mRNA中最常见的表观遗传修饰方式。m^(6)A甲基化的紊乱会导致基因转录和翻译过程异常,从而促进癌症的发生和发展。最近的研究表明,m^(6)A甲基化不仅可以影响肿瘤的细胞增殖和抑制信号网络,还能调节肿瘤免疫原性。该研究聚焦于探讨m^(6)A调节因子在调控肿瘤关键信号通路中的相关机制,并阐述了m^(6)A表观遗传修饰调节免疫检查点的表达方式。这将为理解m^(6)A表观遗传修饰在调节肿瘤免疫逃逸中的作用和机制提供一个新的思路。此外,该文还强调了基于m^(6)A修饰的靶向联合免疫治疗策略的前景和发展方向,这有望提高免疫检查点抑制剂的治疗效果。

m^(6)A(N6-methyladenosine)refers to the methylation modification that is observed at the N6 position of adenosine and is the most prevalent epigenetic modification seen in eukaryotic mRNA.Disruptions in m^(6)A methylation can result in aberrant gene transcription and translation procedures,thereby facilitating the onset and progression of cancer.Recent investigations have indicated that m^(6)A methylation not only impacts tumor cell proliferation and inhibitory networks but also regulates tumor immunogenicity.The objective of this analysis is to investigate the pertinent mechanisms of m^(6)A regulatory factors in governing vital signaling pathways in tumors and elucidate how m^(6)A epigenetic modification controls the expression of immune checkpoints.By undertaking this,this study offers a fresh perspective on the role and mechanism of m^(6)A epigenetic modification in regulating tumor immune escape.Furthermore,the article emphasizes the potential and future direction of targeted combination immunotherapy strategies based on m^(6)A modification,which could enhance the effectiveness of immune checkpoint inhibitors.